Role of matrix metalloproteinases 1, 2, and 9 and tissue inhibitor of matrix metalloproteinase-1 in chronic venous insufficiency

• Published in: Journal of vascular surgery Vol. 34; no. 5; pp. 930 - 938
• Main Authors: Saito, Satoshi, Trovato, Matthew J., You, Ruoxu, Lal, Brajesh K., Fasehun, Funmi, Padberg, Frank T., Hobson, Robert W., Durán, Walter N., Pappas, Peter J.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.11.2001
• Subjects: Blotting, Western; Female; Gene Expression; Humans; Immunohistochemistry; Male; Matrix Metalloproteinase 1 - genetics; Matrix Metalloproteinase 1 - physiology; Matrix Metalloproteinase 2 - genetics; Matrix Metalloproteinase 2 - physiology; Matrix Metalloproteinase 9 - genetics; Matrix Metalloproteinase 9 - physiology; Middle Aged; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tissue Inhibitor of Metalloproteinase-1 - genetics; Tissue Inhibitor of Metalloproteinase-1 - physiology; Transforming Growth Factor beta - metabolism; Venous Insufficiency - enzymology; Venous Insufficiency - metabolism

Purpose: Increased transforming growth factor–β1 (TGF-β1) activity is associated with chronic venous insufficiency (CVI) disease progression and dermal skin pathology. Because TGF-β1 stimulates collagen synthesis and alters the levels of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs),...